Quince Therapeutics, Inc.

QNCXNASDAQHealthcareBiotechnology

$32.03- (-)1Y +1686.56%

As of Oct 16, 2026 close

Market cap: $203.79M
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $0.80$76.86
Volume (live): -
Avg. volume (3M): 30.18K

Quince Therapeutics, Inc. (QNCX) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Quince Therapeutics, Inc. stock.

Analyst Consensus Rating

Investment consensus from 8 professional research analysts

Consensus Rating

Buy

Based on 8 unique analysts

(9 total ratings in last 90 days)

Medium Confidence∞:1 Buy/Sell

Average Price Target

$75.63

+136.12% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest QNCX Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 9, 2026	Tiago Fauth	Raymond James	Initiates	Buy	$72.00
Sep 30, 2026	Albert Lowe	Craig-Hallum	Maintains	Buy	$68.00
Sep 30, 2026	Sam Slutsky	LifeSci Capital	Maintains	Buy	$98.00
Sep 30, 2026	Joseph Schwartz	Leerink Partners	Reiterates	Buy	$68.00
Sep 24, 2026	Seema Sheoran	Rodman & Renshaw	Initiates	Buy	$70.00
Sep 22, 2026	Jonathan Wolleben	Citizens JMP	Upgrades	Buy	$77.00
Aug 18, 2026	Olivia Brayer	Cantor Fitzgerald	Reiterates	Buy	$80.00 → $70.00 −10.00 (−12.5%)
Aug 17, 2026	Olivia Brayer	Cantor Fitzgerald	Reiterates	Buy	$80.00 → $70.00 −10.00 (−12.5%)
Aug 17, 2026	Mazahir Alimohamed	Oppenheimer	Reiterates	Buy	$82.00

Tiago Fauth

Raymond James

BuyInitiates

$72.00

Oct 9

Albert Lowe

Craig-Hallum

BuyMaintains

$68.00

Sep 30

Sam Slutsky

LifeSci Capital

BuyMaintains

$98.00

Sep 30

Joseph Schwartz

Leerink Partners

BuyReiterates

$68.00

Sep 30

Seema Sheoran

Rodman & Renshaw

BuyInitiates

$70.00

Sep 24

Jonathan Wolleben

Citizens JMP

BuyUpgrades

$77.00

Sep 22

Olivia Brayer

Cantor Fitzgerald

BuyReiterates

$80.00 → $70.00

Aug 18

Olivia Brayer

Cantor Fitzgerald

BuyReiterates

$80.00 → $70.00

Aug 17

Mazahir Alimohamed

Oppenheimer

BuyReiterates

$82.00

Aug 17

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 9, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for QNCX?

The analyst consensus rating for QNCX is Buy, based on the latest ratings from 8 analysts over the last 90 days.

What is the average price target for QNCX?

The average 12-month price target for QNCX is $75.63, representing an upside of 136.1% from the Oct 16, 2026 close of $32.03.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.